Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kezar Life Sciences (KZR) Net Cash Flow (2021 - 2025)

Kezar Life Sciences' Net Cash Flow history spans 5 years, with the latest figure at $4.6 million for Q3 2025.

  • For Q3 2025, Net Cash Flow fell 30.29% year-over-year to $4.6 million; the TTM value through Sep 2025 reached $4.1 million, down 50.37%, while the annual FY2024 figure was $6.3 million, 227.37% up from the prior year.
  • Net Cash Flow for Q3 2025 was $4.6 million at Kezar Life Sciences, up from -$2.7 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $66.5 million in Q2 2022 and bottomed at -$40.9 million in Q3 2022.
  • The 5-year median for Net Cash Flow is -$1.6 million (2023), against an average of $939105.3.
  • The largest YoY upside for Net Cash Flow was 1808.32% in 2022 against a maximum downside of 1519.22% in 2022.
  • A 5-year view of Net Cash Flow shows it stood at $5.8 million in 2021, then tumbled by 515.59% to -$24.0 million in 2022, then soared by 137.26% to $9.0 million in 2023, then decreased by 22.23% to $7.0 million in 2024, then crashed by 34.3% to $4.6 million in 2025.
  • Per Business Quant, the three most recent readings for KZR's Net Cash Flow are $4.6 million (Q3 2025), -$2.7 million (Q2 2025), and -$4.8 million (Q1 2025).